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Abstract
In order to determine phenotypic protease and reverse transcriptase inhibitor-associated resistance in HIV subtype C virus,
we have synthetically constructed an HIV-1 subtype C (HIV-1-C) viral backbone for use in a recombinant virus assay. The in
silico designed viral genome was divided into 4 fragments, which were chemically synthesized and joined together by
conventional subcloning. Subsequently, gag-protease-reverse-transcriptase (GPRT) fragments from 8 HIV-1 subtype C-
infected patient samples were RT-PCR-amplified and cloned into the HIV-1-C backbone (deleted for GPRT) using In-Fusion
reagents. Recombinant viruses (1 to 5 per patient sample) were produced in MT4-eGFP cells where cyto-pathogenic effect
(CPE), p24 and Viral Load (VL) were monitored. The resulting HIV-1-C recombinant virus stocks (RVS) were added to MT4-
eGFP cells in the presence of serial dilutions of antiretroviral drugs (PI, NNRTI, NRTI) to determine the fold-change in IC50
compared to the IC50 of wild-type HIV-1 virus. Additionally, viral RNA was extracted from the HIV-1-C RVS and the amplified
GPRT products were used to generate recombinant virus in a subtype B backbone. Phenotypic resistance profiles in a
subtype B and subtype C backbone were compared. The following observations were made: i) functional, infectious HIV-1
subtype C viruses were generated, confirmed by VL and p24 measurements; ii) their rate of infection was slower than viruses
generated in the subtype B backbone; iii) they did not produce clear CPE in MT4 cells; and iv) drug resistance profiles
generated in both backbones were very similar, including re-sensitizing effects like M184V on AZT.
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Introduction
Subtype C of theHumanImmunodeficiencyVirus type 1 (HIV-1)
is accountable for over 50% of the HIV-1 infections worldwide
[1,2,3,4]. Some authors suggest that the global spread of
subtype C might be related to a reduced virulence compared to
other subtypes [4]. However, increased tourism to, and
migration from, the regions where subtype C is most common,
are possibly important factors for an increasing prevalence of
subtype C around the world [5,6].
An adequate resistance-profiling tool requires an assay that
correctly assesses drug resistance for all HIV variants. This can be
a challenge as even quasi-species in a single individual may differ
up to 10% [2]. Additionally, in order to generate correct sensitive/
resistant calls, the sequence interpretation algorithm needs to be
able to integrate the constantly growing knowledge of resistance-
associated mutations (RAMs). This should also include different
possible pathways to anti-retroviral drug resistance among the
different subtypes.
The phenotypic anti-HIV drug resistance assay as described by
Hertogs et al. [7] is based on HIV-1 subtype B (HXB2), as this was
one of the first HIV-1 clones isolated from the DNA of H9 cells
infected with HIV-1IIIB [8]. In that assay, protease and reverse
transcriptase sequences from a patient virus are recombined into
the subtype B backbone, deleted for the protease and reverse
transcriptase sequences, and the recombinant virus is assessed for
the existence of resistance to antiretroviral drugs. We wanted to
investigate whether this HXB2-based system (HIV-1 subtype B)
can be used to assess resistance in protease reverse transcriptase
(GPRT) sequences of non-subtype B viruses.
We constructed an HIV-1 subtypeC backbone as HIV-1 subtype
C is the most prevalent HIV-1 subtype worldwide and therefore an
important diagnostic target. Protease-reverse transcriptase ampli-
cons were generated from HIV-1 subtype C-infected patient
samples and successfully recombined into the subtype C viral
backbone. The resulting viruses allowed to test for drug suscepti-
bility in a subtype C viral context. Subsequently, GPRT amplicons
were isolated from these subtype C viruses and recombined into the
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again tested for drug susceptibility allowing a comparison of the
resistance profiles measured in both HIV subtype backbones.
Materials and Methods
1. Samples
Eight HIV-1 clinical plasma samples with homology to subtype
C in the gag-protease-reverse transcriptase region (GPRT region)
were used. A written informed consent had been obtained for the
samples. All samples were anonymised before transfer and use for
this study. One sample had no resistance-associated mutation
(RAMs) while the remaining 7 samples had at least 8 documented
RAMs (range 8–29, Table 1).
2. Viral RNA extraction
Viral RNA extraction of plasma and virus stocks was carried out
on an EasyMAG (bioMe ´rieux, Boxtel, The Netherlands) accord-
ing to the guidelines of the manufacturer, starting with 600 ml
input material and eluting in 25 ml. If the samples were processed
for viral load determination on the EasyQ (see below), EasyQ
calibrator was added along with the magnetic silica according to
the guidelines of the manufacturer.
3. GPRT amplification and gel analysis
A One-Step RT-PCR amplification (One-Step SuperscriptIII
HiFi, Invitrogen, CA, USA) was used to generate a 2.3 kb HIV-1
fragment (containing the downstream part of GAG and about two
thirds of the adjacent POL region (Protease, Reverse Transcriptase
and part of Integrase)) using the ‘‘39-RT’’ (59-catgagaaatatcacag-
taattggagagcaatg-39) and ‘‘59-OUT’’ (59-gcccctaggaaaaagggctgttgg-
39) primers. RNA input was 10 ml, final volume 35 ml. Subsequent-
ly, a nested PCR was performed (final volume 50 ml, DNA input
5 ml) using the (a) ‘‘39-In’’ (59-ctaggaaaaagggctgttggaaatg-39)a n d
‘‘59-In’’ (59-catctacatagaaggtttctgctcc-39) primers generating a
1.8 kb GPRT fragment for homologous recombination with the
subtype B backbone, or (b) the ‘‘59-Infusion’’ (59-aatgtggaaaggaag-
gacaccaaatgaaag-39) and ‘‘39-Infusion’’ (59-ctcataaccgttcggtggacc-
taaggact-39) primers generating a 1.7 kb GPRT-fragment adapted
for ‘‘In-Fusion’’ cloning in the subtype C backbone (see below). The
In-Fusion amplicon is shorter. In contrast to homologous
recombination, where the overlaps are preferably as long as
possible, the overlapping sequences must be exactly 15 bases long
in the In-Fusion assay. Both nested amplicons encode roughly
the same region of the 39-end of GAG (from aa31 of p7 onwards)
but contain the same coding sequences for protease and reverse
transcriptase (400 aa). To ensure identical mutation profiles, all
virus stocks were sequenced to ascertain that no other non-subtype-
specific mutations might influence the resistance profile (See 2.11).
4. Amplicon purification
Gel extraction of the 1.7 kb GPRT-In-Fusion amplicons was
performed using the QIAquick Gel Extraction Kit (Qiagen),
following the manufacturer’s instructions. The 1.8 kb GPRT
amplicons, used for homologous recombination, were purified
prior to gel analysis, using the QIAquick PCR Purification Kit
(Qiagen), following the manufacturer’s instructions.
5. Design and construction of the HIV-1 subtype C
backbone for In-Fusion-cloning
5.1. Initial sequence design, synthesis and construction of
the HIV-1 subtype C backbone. The in silico design of the
HIV-1 subtype C backbone was based on the subtype C sequence
with accession number AB023804 (www.hiv.lanl.gov). This sequence
lacked partof the 39LTR region, which was completed by adding the
matching bases as present in the 59 LTR (59-GTGGAAAA-
TCTCTAGCA-39). A BstEII restriction site present at position
1534 (acaGGTAACCca – coding for Thr-Gly-Asn-Pro in GAG) was
changed to ‘‘acaGGGAACCca’’ conserving the translation. Also an
AccIII restriction site (TCCGGA) at position 308 (59 LTR) was
modified to CCCGGA for cloning purposes (see below).
5.2. Synthetic production of the HIV-1 subtype C
backbone. The final design of the subtype C sequence was
divided into 4 fragments (flanked by EcoRI and BamHI restriction
sites for cloning purposes), three of which were destined for synthesis
(Fig. 1, fragments I, II, III). The synthesis of the 3 DNA fragments
was performed at Centocor, CA, USA [9,10] as follows: padded
sequences were parsed into contiguous segments of equal
length on both the forward and reverse strands; each segment
was chemically synthesized as an oligonucleotide using GENEW
RITER
TM instrumentation (Centocor) and purified by reversed
phase HPLC (Dionex, Sunnyvale, CA); purified oligonucleotides
were assembled using proprietary gene assembly technology
(Centocor, [9,10] and cloned into a pGEM-3z vector (2743 bp)
using EcoRI and BamHI (Fig. 1). Vector Fragment-I (Fig. 1-A)
contained an EcoRI-BamHI flanking fragment of HIV-1 59-LTR and
GAG, as well as an inserted BstEII restriction site and a small
downstream part of POL (2205 bp). Vector Fragment-II (Fig. 1-B)
containedan EcoRI-BamHIflankingfragmentofHIV-1GAG,aswell
as an inserted BstEII restriction site, the 39 part of POL, a fragment of
ENV (mostly deleted and replaced with a NotI-containing sequence)
and the 39-LTR (3460 bp). Vector Fragment-III (Fig. 1-D) contained
an EcoRI-BamHIflanking fragment of the complete HIV-1 ENV and
the upstream part of the 39LTR (3412 bp). While the V3 envelope
region of AB023804 was predicted to be R5-tropic according to the
Geno2Pheno prediction tool (http://coreceptor.bioinf.mpi-inf.mpg.
de/index.php) and Position Specific Scoring Matrices (PSSM,
http://indra.mullins.microbiol. washington.edu), an R4-tropic virus
was needed for the transfection assay in MT4 host cells. An envelope
sequence retrieved from Los Alamos (subtype C clone
C.ZA.01.01ZARP1) was predicted to be X4-tropic and was used to
design Vector Fragment-III (Fig. 1-D) The fragment containing the
protease and reverse transcriptase region was not synthesized but
PCR-amplified from clinical samples as described above.
5.3. Subcloning of the HIV-1 subtype C backbone. In a
first step vector Fragment-I and vector Fragment-II were joined by
subcloning the EcoRI-BstEII fragment from Vector Fragment-I in
Vector Fragment-II digested with the same enzymes. This resulted
in an HIV-1 subtype C clone (Vector Fragment-I-II - Fig. 1-C)
that had both the majority of POL (replaced by BstEII) and ENV
(replaced by NotI) deleted.
The PacI-AccIII fragment of Vector Fragment-III (Fig. 1-D) was
subcloned in Vector Fragment-I-II (Fig. 1-C) digested withthe same
enzymes. This resulted in a Vector Fragment-I-II-III which only
had the GPRT region deleted, called ‘‘pGEM-HIV-1-C-Dgprt-
BstEII’’. Finally, the vector was linearized by BstEII and a small
artificial sequence (59-GTCACCGCGTGCGATATCGAGCCCG-39) was in-
serted transforming the BstEII site into a BstEII-EcoRV-BstEII site,
to reduce the background during In-Fusion and transformation into
competent cells. This vector was called ‘‘pGEM-HIV-1-C-Dgprt-
BstEII-V’’ (Fig. 1-E). The linearized vector enabled In-Fusion
cloning with the 1.7 GPRT-In-Fusion patient-derived amplicons,
restoring a full genome, infectious HIV-1 clone (Fig. 1-E, Genbank
reference GU474419) (see below). In a phylogenetic tree, the
pGEM-HIV-1-C-Dgprt-BstEII-V sequence (completed with a wild-
type subtype C GPRT sequence) clustered together with the other
HIV-1 subtype C sequences (Fig. 1-F).
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6.1 HIV-1 subtype C backbone. The linearized pGEM-
HIV-1-C-Dgprt-BstEII backbone was combined with the purified
GPRT-In-Fusion amplicon in a molar ratio 1:7 (final volume of
10 ml) and mixed with the dried reaction beads for In-Fusion
according to the guidelines of the manufacturer (In-Fusion
TM 2.0
Dry-Down PCR Cloning Kit – Clontech, Cat. No. 639607 (24
rxns), 639608 (96 rxns)), prior to transformation into bacterial cells
(see 2.7.).
6.2 HIV-1 subtype B backbone. In contrast to the In-Fusion
strategy for the subtype C backbone, a homologous recombination
event strategy was used for the subtype B backbone to generate
infectious virus [7]. Here the BstEII-linearized pGEM-
HXB2Dgprt-BstEII backbone was co-transfected with the 1.8 kb
Table 1. Overview of the clones per sample, day of harvest (subtype C and B), VL and p24 measurements as well as the
corresponding resistance-associated mutations per clone (as referenced by IAS-USA, ANRS) per sample.
log increase Resistance associated mutations
Sample Clone DTH VL p24 DTH Protease Reverse Transcriptase
1 1 14 3.60 2.10 12 10F 15V 20R 36I 43T 46I 54L 63P 69K 71I 74P
82A 84V 90M 93L
41L 44D 67N 74V 98G 101H 118I 181C 184V 190A
210W 215Y 219R 335D
2 18 3.10 2.30 12 10F 15V 20R 36I 43T 46I 54L 63P 69K 71I 74P
82A 84V 90M 93L
41L 44D 67N 74V 98G 101H 118I 181C 184V 190A
210W 215Y 219R 335D
3 11 3.80 2.20 - 10F 15V 20R 36I 43T 46I 54L 63P 69K 71I 74P
82A 84V 90M 93L
41L 44D 67N 74V 98G 101H 118I 181C 184V 190A
210W 215Y 219R 335D
4 18 3.00 2.90 12 10F 15V 20R 36I 43T 46I 54L 63P 69K 71I 74P
82A 84V 90M 93L
41L 44D 67N 74V 98G 101H 118I 181C 184V 190A
210W 215Y 219R 335D
5 11 3.10 1.50 12 10F 15V 20R 36I 43T 46I 54L 63P 69K 71I 74P
82A 84V 90M 93L
41L 44D 67N 74V 98G 101H 118I 181C 184V 190A
210W 215Y 219R 335D
2 1 7 3.70 1.90 7 10F 13V 20R 33F 36I 46I 54V 60E 63P 69K
76V 82A 89I
41L 67N 74V 101E 118I 138A 184V 190A 210W 215Y
335D 371V
2 5 2.50 1.50 6 10F 13V 20R 33F 36I 46I 54V 60E 63P 69K
76V 82A 89I
41L 67N 74V 101E 118I 138A 184V 190A 210W 215Y
335D 371V
3 11 2.70 1.70 7 10F 13V 20R 33F 36I 46I 54V 60E 63P 69K
76V 82A 89I
41L 67N 74V 101E 118I 138A 184V 190A 210W 215Y
335D 371V
4 14 3.10 1.80 7 10F 13V 20R 33F 36I 46I 54V 60E 63P 69K
76V 82A 89I
41L 67N 74V 101E 118I 138A 184V 190A 210W 215Y
335D 371V
3 1 14 3.50 1.80 12 10F 13V 15V 20T 24I 33F 36I 54V 62V 63T
69K 74A 82A 93L
41L 67N 70R 74I 101Q 184V 215Y 219Q 335D
2 7 2.90 2.40 9 10F 13V 15V 20T 24I 33F 36I 54V 62V 63T
69K 74A 82A 93L
41L 67N 70R 74I 101Q 184V 215Y 219Q 335D
3 18 3.20 1.80 7 10F 13V 15V 20T 24I 33F 36I 54V 62V 63T
69K 74A 82A 93L
41L 67N 70R 74I 101Q 215Y 219Q 335D
4 14 3.10 1.40 9 10F 13V 15V 20T 24I 33F 36I 54V 62V 63T
69K 74A 82A 93L
41L 67N 70R 74I 101Q 184V 215Y 219Q 335D
4 1 11 4.00 2.50 8 15V 36I 69K 89M 93L 74V 106M 335D
2 7 3.50 1.30 7 15V 36I 69K 89M 93L 74V 106M 335D
3 11 2.20 1.80 8 15V 36I 69K 89M 93L 74V 106M 335D
5 1 14 2.50 1.70 7 10F 13V 15V 20H 30N 33F 36I 54V 63P 69K
74S 82A 89V 93L
118I 138A 335D
6 1 14 1.70 1.40 12 10F 15V 20V 36I 46I 50V 54V 63H 69K 71V
73S 82A 85V 89V 90M 93L
41L 67G 69D 74V 98G 103N 118I 184V 215F 219Q
335D 371V
2 18 2.80 2.10 12 10F 15V 20V 36I 46I 50V 54V 63H 69K 71V
73S 82A 85V 89V 90M 93L
41L 67G 69D 74V 98G 103N 118I 184V 215F 219Q
335D 371V
3 7 4.10 1.60 8 10F 15V 20V 36I 46I 50V 54V 63H 69K 71V
73S 82A 85V 89V 90M 93L
41L 67G 69D 74V 98G 103N 118I 184V 215F 219Q
335D 371V
4 16 2.40 2.50 8 10F 15V 20V 36I 46I 50V 54V 63H 69K 71V
73S 82A 85V 89V 90M 93L
41L 67G 69D 74V 98G 103N 118I 184V 215F 219Q
335D 371V
7 1 14 3.30 2.40 9 10F 15V 20R 36I 43T 46I 54L 63P 69K 71V
74P 82A 84V 90M 93L
41L 44D 67N 74V 98G 101H 118I 181C 184V 190A
210W 215Y 219R 335D
2 14 2.20 1.70 12 10F 15V 20R 36I 43T 46I 54L 63P 69K 71V
74P 82A 84V 90M 93L
41L 44D 67N 74V 98G 101H 118I 181C 184V 190A
210W 215Y 219R 335D
8 1 6 2.50 2.20 5 - -
Average 12.25 3.02 1.94 9.04
Stdev 4.07 0.61 0.42 2.38
‘‘DTH’’ Days to harvest.
doi:10.1371/journal.pone.0019643.t001
HIV-1 Subtype B and C Backbone Phenotyping
PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e19643GPRT fragment in an MT4 cell line, resulting in a full-genome
infectious virus (See below).
7. Transformation into MAX EfficiencyH Stbl2
TM cells
A total of 10 ml of diluted In-Fusion reaction mix (dilution
prepared during In-Fusion cloning – see 2.6.) was added to the
MAX EfficiencyH Stbl2
TM cells (Invitrogen, Cat. No. 10268-019)
and treated according to the guidelines of the manufacturer. LB-
ampicillin agar plates were incubated at 30uC for approximately
24 hours.
8. DNA preparation
Overnight liquid LB-ampicillin cultures (3 ml) were prepared
from single colonies (n=8/sample) and DNA was prepared using
the PureLink HQ 96 Plasmid DNA Purification Kit (Invitrogen,
Cat. No. K2100-96), according to the guidelines of the manufac-
turer. The plasmid integrity was checked by restriction analysis
using NdeI (New England Biolabs) and the resulting full HIV-1-C
genome plasmids (n=1–5 per sample, Table 1) were used for
transfection.
9. Generation of recombinant virus stocks - Antiviral
experiment
MT4 cells were transfected using the Amaxa nucleofection
technology (Amaxa Biosystems, Cologne, Germany) according to
the manufacturer’s instruction. For the subtype C full genome
plasmids: 10 ml plasmid (1 mg/ml) of the HIV-1 subtype C clones
(see 2.8.) was transfected, using pulsation program A-27, into
2.5610
6 MT4-eGFP cells, resuspended in 100 ml solution V.
Identical settings were applied for the subtype B transfection but
the full genome plasmid was replaced by 1 mlp G E M -
HXB2Dgprt-BstEII-linearized plasmid and 9 ml of the 1.8 kb
GPRT amplicon (see 2.6.2). Transfected cells were cultured at
37uC and 5% CO2. Infection rate and CPE were monitored on a
daily basis until all cells were infected (monitored by eGFP
production) or until full cytopathic effect (CPE) was reached after
which the recombinant virus was harvested. The resulting virus
stocks were titrated and added to MT4-eGFP cells in the
presence of serial dilutions of antiretroviral drugs (PI, NNRTI,
N(t)RTI) to determine the fold-change in the concentration at
which 50% of the virus is inhibited (IC50) compared to the IC50
Figure 1. Subcloning strategy of the vector containing the HIV-1 subtype C-Dgprt backbone. Fragment I (A) and Fragment II (B) were
digested using BstEII and EcoRI and religated resulting in an HIV-1 subtype C clone lacking a part of GAG, protease and reverse Transcriptase and
most of ENV (Fragment I-II (C)). Fragment I-II was linearized using PacI and AccIII to insert the Env region from Fragment III (D) resulting in a final
clone, pGEM-HIV-1-C-Dgprt-BstEII-V, that can be linearized using BstEII/EcoRV, ready for In-Fusion cloning with the 1.7 kb GPRT amplicon.N pGEM-
HIV-1-C-Dgprt-BstEII-V+GPRT (wild type sequence).
doi:10.1371/journal.pone.0019643.g001
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were performed as indicated in fig. 2.
10. Viral load and p24 determination
Viral loads were determined on the EasyQ, using the NucliSens
EasyQ HIV-1 v1.2 (Cat nr. 285 036, BioMe ´rieux) as described by
the manufacturer.
P24 measurements were performed on the MiniVidas (bioMe ´r-
ieux) using the Vidas P24 II (P24) kit (Cat. nr. 30117, bioMe ´rieux)
according to the guidelines of the manufacturer.
11 Sequencing
Sequencing reactions were performed with the Big Dye
Terminator Cycle Sequencing Kit v3.1 (Cat nu. 4337457, Applied
Biosystems, CA, USA). The primers used for the sequence
confirmation of the pGEM-HIV-1-C-Dgprt-BstEII-V backbone
after cloning are listed in Table 2-A, the primers used to sequence
the GPRT amplicons are listed in Table 2-B.
The purification was performed using the DyeEX (Qiagen)
purification kit, according to the guidelines of the manufacturer.
The ABI3730 XL (Applied Biosystems) performed the sequence
detection and analysis was done using ‘‘Seqscape’’ (Applied
Biosystems software).
Results
1. Generation of HIV-1 subtype C recombinant virus
stocks
A total of 8 different HIV-1 subtype C amplicons were
processed according to the scheme depicted in Figure 2. A total
of 8 colonies were picked per In-Fusion reaction (1 In-Fusion/
amplicon) and sequenced, to verify a correct insert of the GPRT
Figure 2. Experimental flow. Flow of the testing of the subtype C GPRT amplicons in the pGEM-HIV-1-C-Dgprt-BstEII-V (pHIV-1-C-Dgprt) and the
pGEM-HXB2-Dgprt-BstEII (pHIV-1-B-Dgprt) backbones. ‘‘TRF’’: transfection (Amaxa); ‘‘FC’’: Fold Change; Red boxes: phenotypes; Green boxes:
genotypes.
doi:10.1371/journal.pone.0019643.g002
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A - pGEM-HIV-1-C-Dgprt-BstEII backbone sequencing primers
Primer name Sequence 59-39 Primer name Sequence 59-39
HXB2-F1073 AAGACACCAAGGAAGC HXB2-R4295 CATTGCTCTCCAATTACTGTGATATTTCTCATG
HXB2-F1494 CATAGCAGGAACTACTAGTA HXB2-R4646 AAATTCCTGCTTGATTCCCG
HXB2-F1829 ATGACAGCATGTCAGGGAGT HXB2-R4961 TTCCAGAGGAGCTTTGC
HXB2-F2008 GCCCCTAGGAAAAAGGGCTGTTGG HXB2-R5504 GTTATTAATGCTGCTAGTGCC
HXB2-F2012 CTAGGAAAAAGGGCTGTTGGAAATG HXB2-R5899 GGTACAAGCAGTTTTAGGC
HXB2-F2142 CAGACCAGAGCCAACAGCCCC HXB2-R6147 TCTATGATTACTATGGACC
HXB2-F2261 CACTCTTTGGCAACGACCC HXB2-R664 TTCGCTTTCAAGTCCCTGTTCG
HXB2-F2469 GGTACAGTATTAGTAGGACC HXB2-R6834 GGACTGTAATGACTGAGG
HXB2-F2696 AATTGGGCCTGAAAATCC HXB2-R7345 TGCGTTACAATTTCTGGGTCC
HXB2-F2871 GTACTGGATGTGGGTGATGC HXB2-R7668 CACTTCTCCAATTGTCCC
HXB2-F3222 CCTCCATTCCTTTGGATGGG HXB2-R8174 TTGCGATTCTTCAATTAAGG
HXB2-F324 AACTGCTGACATCGAGCTTGC HXB2-R835 ATCGATCTAATTCTCCCC
HXB2-F3330 GTGGGAAAATTGAATTGGG HXB2-R8477 CCGTTCACTAATCGAATGG
HXB2-F3771 GCCACCTGGATTCCTGAGTG HXB2-R9019 GTACCTGAGGTGTGACTGGA
HXB2-F4308 AACCTGCCACCTGTAGTAGC HXB2-R9080 CCCTTTTCTTTTAAAAAGTGGC
HXB2-F4809 TACAGTGCAGGGGAAAG HXB2-R9100 GAATTAGCCCTTCCAGTCCC
HXB2-F5265 AGAAAGAGACTGGCATTTGG pGEM-F10263 ATTGTTTGCAAACCTGAATAGC
HXB2-F5733 GCCATAATAAGAATTCT pGEM-F10723 ATCTTGTTCAATCATTGATCGG
HXB2-F6013 CAGTCAGACTCATCAAGC pGEM-F11011 CTTCCTCATCTGCAGGTTCC
HXB2-F644 GAACAGGGACTTGAAAGCG pGEM-F11885 GTATTTCACACCGCATATGG
HXB2-F6464 CCCACAAGAAGTAGTATTGG pGEM-F12495 TAAAGTTCTGCTATGTGGCG
HXB2-F6469 AAGAAGTAGTATTGGTAAATGTGA pGEM-F13102 AGACAGATCGCTGAGATAGG
HXB2-F7220 CATTAGTAGAGCAAAATGG pGEM-F13585 GGGTTGGACTCAAGACGATAG
HXB2-F761 TTTGACTAGCGGAGGCTAGAAG pGEM-F13983 CCCTGATTCTGTGGATAACC
HXB2-F7919 GTTGCAACTCACAGTCTGG pGEM-F14414 TATAGGGCCTCCTAGCTACC
HXB2-F8332 CTATAGTGAATAGAGTTAGG pGEM-F14817 CTGTTTGGTGTGGCTATCAG
HXB2-F8658 GTTAGCTTGCTCAATGCCAC pGEM-F15347 CTATTACCACTGCCAATTACC
HXB2-F8754 CCTAGAAGAATAAGACAGG pGEM-F9857 AGTACTTGGAAGAAGCCACC
HXB2-F9000 TCCAGTCACACCTCAGGTAC pGEM-R10289 TTGAAGCTATTCAGGTTTGC
HXB2-R1337 TCTTGTGGGGTGGCTCCTTC pGEM-R10922 TACCCCAGTCTCAGGTTTTC
HXB2-R1682 TCTACATAGTCTCTAAAGGG pGEM-R11228 ATACGACTCACTATAGGGCG
HXB2-R2164 GTGGGGCTGTTGGCTCTGGT pGEM-R12019 GTCTGTAAGCGGATGCCGGGAGC
HXB2-R2414 GATAAAACCTCCAATTCC pGEM-R12462 TATCCCCAGAGACCTTCGAG
HXB2-R2620 CATTGTTTAACTTTTGGGCC pGEM-R12765 AAGGCGAGTTACATGATCCC
HXB2-R2817 CTTCCCAGAAGTCTTGAGTTC pGEM-R13084 TTGCCTGACTCCCCGTCG
HXB2-R3030 GGAATATTGCTGGTGATCC pGEM-R13534 GCAGAGCGAGGTATGTAGG
HXB2-R3273 GTACTGTCCATTTATCAGG pGEM-R13975 CAGGAAAGAACATGTGAGC
HXB2-R3511 GGGTCATAATACACTCCATG pGEM-R14379 TCTAGAGTCGACCTGCAGG
HXB2-R3794 CTCCCACTCAGGAATCC pGEM-R14869 GAAAAGCAAACAAGAAAGGGG
HXB2-R3837 CTAACTGGTACCATAATTTCACTAAGGGAGG pGEM-R15376 CAAACCACAACTAGAATGCAG
HXB2-R3879 CATCTACATAGAAAGTTTCTGCTCC pGEM-R9795 CAAGGCCTCTCACTCTCTG
B - GPRT amplicons sequencing primers
Primer name Sequence 59-39 Primer name Sequence 59-39
F1 GAGAGCTTCAGGTTTGGGG F4 CAGACCAGAGCCAACAGCCCC
F2 AATTGGGCCTGAAAATCC F6 GGTACAGTATTAGTAGGACC
F3 CCTCCATTCCTTTGGATGGG F7 GTACTGGATGTGGGTGATGC
F5 CACTCTTTGGCAACGACCC F8 GTGGGAAAATTGAATTGGG
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retained for further processing (Samples 1–7, Table 1). Only one
clone of sample 8 (no RAMs, Table 1) was retained and used as a
subtype C wild-type reference to calculate fold-changes (see
below).
2. Phenotypic characteristics of HIV-1 subtype C and
subtype B recombinant virus stocks
The HIV-1 subtype C virus stock cultures were monitored on a
daily basis for spread of infection, viral load (VL) and p24
production (Table 1). Some viruses replicated very fast and
infected almost all cells within 7 days (n=6, Table 1). A majority
however, replicated slowly and needed up to 18 days to infect all
cells (average time and standard deviation were 12.25 days 64.07,
Table 1). No clear cytopathogenic effect (CPE) was observed
among the HIV-1 subtype C-infected cells and hence spread of
infection needed to be monitored on the basis of fluorescence. As
an example, the complete monitoring of the clones of sample 4 is
shown in Fig. 3. Here, a gradual increase of fluorescence in cell
clusters could be observed from day 4 (Fig. 3A - 1) over day 6
(Fig. 3A - 2) to the final point on day 11 where the RVS was
harvested (Fig. 3A - 3). As in the example, harvesting occurred at
the moment where nearly all cell clusters were completely
fluorescent, which coincided with the moment at which no or a
smaller increase in viral load was measured compared to the
previous day. Similar curves were observed for p24 measurements.
On average, a 3.02 log 60.61 increase in VL and a 1.94 log 60.42
increase in p24 production was observed (Table 1).
After harvesting the subtype C viruses, RNA was extracted,
amplified and recombined into an HIV-1 subtype B backbone.
The resulting recombinant viruses were sequenced to ensure a
complete mutation analysis of the GPRT region (Fig. 2). The
corresponding HIV-1 subtype B clones (Fig. 2, Table 1) grew
faster (average 9.0462.38 days until harvesting) compared to
HIV-1 subtype C and gave clear CPE. One amplicon failed to
generate a replicating virus after transfection in the subtype B
backbone (sample 1, clone 3, Table 1).
3. Genotypic analysis of HIV-1 GPRT subtype C sequence
in the subtype C and subtype B backbones
Identical GPRT sequences (Table 1; Fig. 2, Ia) were found for
all virus stocks derived from the same amplicon except for one
clone lacking 184V (Sample 3, Clone 3; Table 1). All genotypes
remained unaltered during the process of re-culturing in either
backbone (Fig. 2, Ib, IIa and IIb).
4. Antiviral drug susceptibility testing of virus stocks
generated with the pGEM-HIV-1-C-Dgprt-BstEII vs. the
pGEM-HXB2-Dgprt-BstEII backbones but carrying
identical GPRT fragments
Fold-change (FC) values were calculated by dividing the IC50
values of the virus stocks harboring RAMs (Samples 1–7; Table 1)
Figure 3. Kinetics of HIV-1 subtype C virus production. A. viral load and pictures of fluorescence (day 4(1); day 6 (2); day 11 (3)); B: p24
measurements for the three clones of sample 4.
doi:10.1371/journal.pone.0019643.g003
B - GPRT amplicons sequencing primers
Primer name Sequence 59-39 Primer name Sequence 59-39
R1 CTCCCACTCAGGAATCC R2 GTACTGTCCATTTATCAGG
R3 CTTCCCAGAAGTCTTGAGTTC R4 CTAACTGGTACCATAATTTCACTAAGGGAGG
R5 GGGTCATAATACACTCCATG R7 CATTGTTTAACTTTTGGGCC
R6 GGAATATTGCTGGTGATCC R8 GATAAAACCTCCAATTCC
doi:10.1371/journal.pone.0019643.t002
Table 2. Cont.
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amplicon (Clinical sample 8 without RAMs for the subtype C
backbone, HXB2 for the subtype B backbone, Table 1). Scatter
plots (1346 paired FC) showing the relationship between the FC
values of the virus stocks carrying the GPRT subtype C
amplicon in a subtype C backbone vs. FC values of the virus
stocks carrying the GPRT subtype C amplicon in a subtype B
backbone are shown in figure 4. The plots demonstrate an
overall similarity in FC between virus stocks generated from a
subtype C amplicons recombined in subtype B and a subtype C
backbone for all drug classes (Fig. 4-A, B, C, D). Correlations
were high and very similar among the three drug classes:
R
2=0.88 (Fig. 4-A, all drug classes), 0.88 (Fig. 4-B, NRTI), 0.90
(Fig. 4-C, NNRTI) and 0.87 (Fig. 4-D, PI). The FC of the
samples analyzed covered the entire resistance spectrum from
virus fully susceptible to fully resistant to one or more drugs. The
ratio FCSubtype B/FCSubtype C for most drugs was close to one
(Fig. 4-E), indicating that the observed fold-change values of the
GPRT amplicons in the subtype C backbone were very similar
to the FC observed for that same amplicons in the subtype B
backbone. However, some differences were observed. The FC
ratio was significantly different from 1 (p,0.05) for emtricitabine
(FTC, p=0.031), nevirapine (NVP, p=0.043), etravirine (ETR,
p=0.033), lopinavir (LPV, p=0.0041) and darunavir (DRV,
p=0.002). The ratios for FTC (0.50) and ETR (0.67) suggest
that, for these drugs, the FC in the subtype C backbone is higher
than in the subtype B backbone, whereas for nevirapine (1.61),
lopinavir (1.86) and darunavir (1.78) the opposite is observed
(Fig. 4-E).
5. Single mutation effects on FC
Clone 3 of Sample 3 (Table 1) enabled us to investigate the
effect of a single RAM (M184V in RT) on the FC of viruses with
the subtype C GPRT sequence inserted in the HIV-1 Subtype B
and C backbones. In RT, a change at position 184 from
methionine to valine results in an increase in FC for 3TC
[11,12] and FTC [13] while it decreases the FC for AZT, d4T and
TDF [14]. This effect was observed with both types of backbone as
shown in Fig. 5. The increase in FC is most pronounced and
highly significant (p=,0.0001) for both 3TC and FTC and for
both subtype backbones. The resensitizing effect for AZT was
highly significant (p,0.0001) in both subtype backbones while it
was significant (p,0.05) only in the subtype C backbone for d4T
(pC=0.046; pB=0.2576) and TDF (pC=0.0267; pB=0.1257).
FCs for ddI and ABC were not significantly affected by the
presence of 184V.
Discussion
Synthetic biology enabled the construction of a fully replicat-
ing, infectious HIV-1 subtype C virus starting from an in silico
design. Although promising, this approach is still in its infancy
and only achieved at a relatively high cost, especially when whole
functional systems are constructed [15,16,17,18,19]. This is true
Figure 4. Scatter plots of FC of subtype C amplicons recombined in subtype B and subtype C backbones. (A–D) X-axis: Subtype B and Y-
axis: subtype C for 1346 pairs; Black line x=y; (A) all drug classes (R
2=0.88); (B) NRTIs (R
2=0.88); (C) NNRTIs (R
2=0.90); (D) PIs (R
2=0.87); (E) Analysis of
the pair-wise comparison of differences in FCs per clone and per drug, Ratio FCSubtype B/FCSubtype C (Average, Red squares) and P-value (Black
diamonds).
doi:10.1371/journal.pone.0019643.g004
Figure 5. Boxplot illustrating the effect of RAM 184V on the NRTI FC in a subtype B and C backbone. Blue=HIV-1 subtype B backbone;
Green=HIV-1 subtype C backbone; ‘‘+’’=mutation 184V is present in RT; number under block=number of observed FC. P values have been
calculated for each subtype for FC with mutation vs. FC without mutation.
doi:10.1371/journal.pone.0019643.g005
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expectations for Synthetic Biology go much further, evidenced by
the BioBrick Foundation (www.biobricks.org), the iGEM compe-
tition (2010.igem.org) and several minimal genome projects
[20,21,22,23] aimed at generating a suitable chassis. We were
interested in creating an HIV subtype C backbone to verify the
validity of the resistance predictions performed on non-subtype B
amplicons in a routine setting. As suggested by Church [24],
safety and control were key operating factors and hence, the idea
of creating a synthetic virus was presented to an international
ethics committee that gave several recommendations. The
committee concluded that identical safety measures applied to
this work as to any other (research) work performed on viruses in
our laboratories and that any findings needed to be reported. The
committee further recommended that each research step should
be carefully monitored, assessed and documented in order to
(proactively) contain and resolve any possible issues.
Although the synthetic construction of the subtype C backbone
might be a first for HIV, the first virus constructed in the absence
of natural template was the polio virus in 2002 [25], followed in
the next year by the assembly of the complete infectious genome of
bacteriophage_X174 (5,386 bp) from a single pool of chemically
synthesized oligonucleotides [19]. Currently larger projects are still
ongoing, mostly referred to as ‘‘minimal genome’’ projects as
discussed in Rabinow et al. [26] and Gibson et al. [23].
The aim of this study was to investigate whether the drug
resistance profile of an HIV-1 subtype C GPRT amplicon is
correctly assessed when introduced into an HIV-1 subtype B
backbone.
To generate a unique set of fully characterized HIV-1 subtype
C viruses for our study, we chose for a clonal approach by
amplifying subtype C GPRT sequences from patient samples
infected with HIV-1 subtype C and cloning these sequences by In-
Fusion into our HIV-1 subtype C backbone. There are multiple
reasons for the decision not to generate virus directly from patient
samples: (a) these assays are often performed on freshly isolated
donor lymphocytes [27] and we had only access to frozen plasma
samples; (b) the isolation and culturing of virus from these
lymphocytes is time-consuming and very labor-intensive and (c)
the prolonged culture times of this kind of assay have been shown
to select for subpopulations of HIV-1 variants [28] which could
influence the drug susceptibility profile. Additionally, these
patients have received Highly Active Anti-Retroviral Therapy
(HAART) and therefore might have a rather wide range of
different quasi-species, hence the clonal approach ensured a strict
selection of mutations and allowed a focused resistance profiling in
the subtype C background.
A recombinant virus assay strategy was used for the HIV-1
subtype B virus generation. In essence, this generated the same
result as the clonal In-Fusion strategy, but is faster since the
transformational step in E. coli (required to make a selection of
mutations from the pool of quasi-species) could be omitted. To
ensure that identical mutations were present in both backbones,
the recombinant subtype B viruses were sequenced to control that
no other non-subtype-specific mutations might influence the
resistance profiling.
The HIV-1 subtype C backbone construct was made similar to
the construct described by Hertogs et al. [7]. Both backbones
generated X4 viruses (required for MT4 infection) and have the
same regions deleted for insertion of identical GPRT amplicons.
The clonal approach allowed selection of identical viral protease
and reverse transcriptase sequences among clones derived from
each sample. Functionality of the viral constructs (virus produc-
tion) was primarily illustrated by spread of infection (monitored by
CPE and fluorescence), and supported by the P24 and viral load
increase. However, the nature of this cell-based assay makes a
linear comparison between viral titer, viral load and P24 content
impossible as investigated by Marozsan et al. [29]. Direct
comparisons are impossible because P24 and viral load assays
can only measure increase or decrease of targets, but cannot
differentiate between functional and non-functional virions (hence
free or incorporated RNA or P24).
Differences observed during culturing were clear (slower
infection rates and nearly no CPE in subtype C viruses as
compared to subtype B viruses) and are most probably due to the
subtype-specific characteristics of the HIV-1 subtype C virus,
which have also been observed and described by other authors
[30,31]. In fact, the observation of these subtype-related
differences in our synthetic viruses, only strengthens the validity
of our resistance profiling experiment as they show that our
synthetic viruses behave in a similar fashion to naturally occurring
HIV-1 subtype C viruses that have been studied.
The remaining question is whether HAART resistance profiles
of GPRT are comparable between HIV-1 subtype B and subtype
C, even if both seem to have clearly different viral kinetics e.g.
regarding CPE. Directly related to this, is the obvious question
whether resistance profiling of a subtype C GPRT sequence in a
subtype B backbone is feasible. If differences were observed, this
could have far-reaching diagnostic consequences.
Thisfirstexploratorystudyindicatesthattherewerenodifferences
inFCbetween phenotypicresistance assessed inthe subtypeB and C
backbones for 13 out of the 18 drugs tested. For FTC, NVP and
ETR the differences were close to the significance level of p=0.05,
whereas highly significant (p,0.05) differences were observed for
LPV and DRV. While the FC in subtype C backbone seemed to be
higher compared to the B backbone for FTC (ratio B/C=0.50) and
ETR (ratio B/C=0.67), the opposite was found for NVP (ratio B/
C=1.61), LPV (ratio B/C=1.86) and DRV (ratio B/C=1.78). As
this was a proof of concept study, the number of tested samples was
limited. An analysis of a greater number of clinical HIV-1 subtype C
samples is ongoing and will confirm whether the trends observed for
these drugs are indeed significant.
With respect to the effect of individual mutations, FC is affected
in similar ways in both subtypes as demonstrated in the analysis of
the M184V mutation (increase in FC for 3TC and FTC,
resensitization for AZT, d4T, TFV).
In conclusion, we successfully constructed a synthetic HIV-1
subtype C backbone for a recombinant virus phenotyping assay.
The resulting recombinant subtype C viruses seemed less
virulent compared to subtype B (e.g., no CPE) as has been
observed in previous HIV-1 subtype C viral studies, but the
generated resistance profiles were similar compared to the
profiles obtained in an HIV-1 subtype B backbone for the
majority of the drugs.
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